RCKT insider transaction filings
ROCKET PHARMACEUTICALS, INC. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-20. Screen RCKT transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-20 | 4 | Wilson Martin — General Counsel | Sale (S): 631 @ $3.38 | EDGAR |
| 2026-08-20 | 4 | Shah Gaurav — CEO | Sale (S): 2,293 @ $3.38 | EDGAR |
| 2026-08-17 | 4 | Wilson Martin — General Counsel | Sale (S): 3,493 @ $3.38 | EDGAR |
| 2026-08-17 | 4 | Shah Gaurav — CEO | Sale (S): 2,837 @ $3.38 | EDGAR |
| 2026-08-13 | 4 | Chaudhuri Sarbani — See Remarks | Sale (S): 4,701 @ $3.50 | EDGAR |
| 2026-08-13 | 4 | Stevens Christopher James — Chief Operating Officer | Sale (S): 36,658 @ $3.50 | EDGAR |
| 2026-08-05 | 4 | Stevens Christopher James — Chief Operating Officer | Grant/award (A): 73,313 @ $0 · Grant/award (A): 101,428 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | SOUTHWELL DAVID P — Director | Other (J): 150,000 @ $0 | EDGAR |
| 2026-07-06 | 4 | WONG RODERICK — Director, 10% owner | Grant/award (A): 27,832 @ $0 · Grant/award (A): 78,960 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | Fong Peter — Director | Grant/award (A): 22,862 @ $0 · Grant/award (A): 64,860 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | Dolsten Mikael — Director | Grant/award (A): 22,862 @ $0 · Grant/award (A): 64,860 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | Malik Fady Ibraham — Director | Grant/award (A): 22,862 @ $0 · Grant/award (A): 64,860 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | BOESS CARSTEN — Director | Grant/award (A): 22,862 @ $0 · Grant/award (A): 64,860 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | SOUTHWELL DAVID P — Director | Grant/award (A): 22,862 @ $0 · Grant/award (A): 64,860 (derivative) @ $0 | EDGAR |
| 2026-05-28 | 4 | Militello John — See Remarks | Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 2,000 (derivative) · +11 more | EDGAR |
| 2026-05-26 | 4 | Shah Gaurav — CEO | Option exercise (M): 76,490 @ $1.69 · Sale (S): 55,684 @ $3.09 · Option exercise (M): 76,490 (derivative) @ $1.69 | EDGAR |
| 2026-05-21 | 4 | Shah Gaurav — CEO | Sale (S): 2,409 @ $3.01 | EDGAR |
| 2026-05-21 | 4 | Wilson Martin — General Counsel | Sale (S): 662 @ $3.01 | EDGAR |
| 2026-05-21 | 4 | Militello John — See Remarks | Sale (S): 384 @ $3.01 | EDGAR |
| 2026-05-14 | 4 | Wilson Martin — General Counsel | Sale (S): 3,361 @ $3.61 | EDGAR |
| 2026-05-14 | 4 | Shah Gaurav — CEO | Sale (S): 2,728 @ $3.61 | EDGAR |
| 2026-05-14 | 4 | Militello John — See Remarks | Sale (S): 855 @ $3.61 | EDGAR |
| 2026-05-11 | 4 | Chaudhuri Sarbani — See Remarks | Sale (S): 17,650 @ $3.84 | EDGAR |
| 2026-02-20 | 4 | Militello John — See Remarks | Sale (S): 1,157 @ $3.34 | EDGAR |
| 2026-02-20 | 4 | Shah Gaurav — CEO | Sale (S): 5,990 @ $3.34 | EDGAR |
| 2026-02-20 | 4 | Wilson Martin — General Counsel | Sale (S): 1,376 @ $3.34 | EDGAR |
| 2026-02-18 | 4 | Wilson Martin — General Counsel | Sale (S): 12,253 @ $3.31 | EDGAR |
| 2026-02-18 | 4 | Militello John — See Remarks | Sale (S): 3,726 @ $3.31 | EDGAR |
| 2026-02-18 | 4 | Shah Gaurav — CEO | Sale (S): 12,279 @ $3.31 | EDGAR |
| 2026-02-13 | 4 | Shah Gaurav — CEO | Grant/award (A): 286,028 @ $0 · Grant/award (A): 870,648 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | Militello John — See Remarks | Grant/award (A): 29,982 @ $0 · Grant/award (A): 45,018 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | Wilson Martin — General Counsel | Grant/award (A): 311,813 @ $0 · Grant/award (A): 468,187 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | Rizvi Syed Ali-aamir — Chief Medical Officer | Grant/award (A): 61,963 @ $0 · Grant/award (A): 93,037 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | Stevens Christopher James — Chief Operating Officer | Grant/award (A): 61,963 @ $0 · Grant/award (A): 93,037 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | Chaudhuri Sarbani — See Remarks | Grant/award (A): 125,924 @ $0 · Grant/award (A): 189,076 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Bjork Elisabeth — Director | Purchase (P): 10,000 @ $3.44 | EDGAR |
| 2025-11-20 | 4 | Militello John — See Remarks | Sale (S): 1,086 @ $2.98 | EDGAR |
| 2025-11-20 | 4 | Schwartz Jonathan David — See Remarks | Sale (S): 2,545 @ $2.98 | EDGAR |
| 2025-11-20 | 4 | Shah Gaurav — CEO, Director | Sale (S): 6,276 @ $2.98 | EDGAR |
| 2025-11-20 | 4 | Wilson Martin — General Counsel | Sale (S): 1,646 @ $2.98 | EDGAR |
| 2025-11-10 | 4 | Wilson Martin — General Counsel | Grant/award (A): 100,000 @ $0 | EDGAR |
| 2025-10-16 | 4 | Militello John — See Remarks | Sale (S): 19,841 @ $3.96 · Sale (S): 5,514 @ $3.96 · Sale (S): 3,005 @ $3.97 · Sale (S): 558 @ $3.98 | EDGAR |
| 2025-10-08 | 4 | Rizvi Syed Ali-aamir — Chief Medical Officer | Grant/award (A): 283,018 @ $0 · Grant/award (A): 62,893 @ $0 · Grant/award (A): 383,854 (derivative) @ $0 | EDGAR |
| 2025-10-03 | 4 | Fong Peter — Director | Grant/award (A): 23,333 @ $0 · Grant/award (A): 30,000 @ $0 | EDGAR |
| 2025-09-23 | 4 | RTW INVESTMENTS, LP — Director, 10% owner WONG RODERICK — Director, 10% owner | Option exercise/expiry (X): 1,000,000 @ $40.03 · Other (J): 1,000,000 @ $3.10 · Option exercise/expiry (X): 41,000 @ $19.09 · Other (J): 41,000 @ $3.10 · Option exercise/expiry (X): 59,000 @ $17.81 · Other (J): 59,000 @ $3.10 · +3 more | EDGAR |
| 2025-09-09 | 4 | Militello John — See Remarks | Grant/award (A): 40,000 @ $0 | EDGAR |
| 2025-09-09 | 4 | Wilson Martin — General Counsel | Grant/award (A): 150,000 @ $0 | EDGAR |
| 2025-09-09 | 4 | Schwartz Jonathan David — See Remarks | Grant/award (A): 80,000 @ $0 | EDGAR |
| 2025-08-27 | 4 | Bjork Elisabeth — Director | Purchase (P): 10,000 @ $3.41 | EDGAR |
| 2025-08-20 | 4 | Militello John — See Remarks | Sale (S): 699 @ $3.06 · Sale (S): 361 @ $3.00 | EDGAR |
Recent 8-K events — ROCKET PHARMACEUTICALS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-12 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-21 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-28 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-27 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RCKT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →